COMMUNIQUÉS West-GlobeNewswire

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
28/03/2024
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug [...]
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
28/03/2024
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid [...]
Ardelyx, Inc. Reports Employment Inducement Grants
28/03/2024
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
ArriVent BioPharma Reports Full Year 2023 Financial Results
28/03/2024
Company progresses the development of furmonertinib with a data readout planned for 2024 Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial [...]
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
28/03/2024
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to [...]
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
28/03/2024
The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial. The serial procedures were well tolerated without observed dose-limiting toxicity. A second cohort [...]
CervoMed to Participate in Upcoming Investor Conferences
28/03/2024
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will [...]
Sharecare announces fourth quarter and full year 2023 financial results and operational highlights
28/03/2024
ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter and year ended [...]
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
28/03/2024
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a [...]
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
28/03/2024
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
28/03/2024
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical [...]
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
28/03/2024
Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on [...]
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
28/03/2024
Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage [...]
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
28/03/2024
WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter [...]
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
28/03/2024
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received [...]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28/03/2024
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever [...]
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
28/03/2024
Publication of annual report for financial year 2023 Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board members Extraordinary Shareholders’ Meeting [...]
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update
28/03/2024
97 patients enrolled TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock [...]
Dyadic Reports 2023 Full Year Results and Recent Company Progress
28/03/2024
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody [...]

Pages